FIB-4 Score of 0.67: Low Risk for Advanced Liver Fibrosis
A FIB-4 score of 0.67 indicates low risk for advanced liver fibrosis and requires no immediate further evaluation, but should be reassessed in 1-3 years if metabolic risk factors are present.
Risk Stratification
Your FIB-4 score of 0.67 falls well below the established threshold of 1.3 (or 2.0 if you're over 65 years old) that indicates increased fibrosis risk 1, 2. This score has a negative predictive value of ≥90% for excluding advanced fibrosis 2, meaning there is approximately a 90% or greater probability that you do not have significant liver scarring.
What This Score Means:
- Below 1.3: Low risk - no further evaluation needed 1
- 1.3-2.67: Intermediate risk - requires additional testing
- Above 2.67: High risk - referral to hepatology recommended
Your score of 0.67 places you firmly in the low-risk category, regardless of your age.
Clinical Context Matters
The interpretation of FIB-4 depends on your underlying condition:
For Hepatitis C: A score <1.45 has 94.7% negative predictive value for severe fibrosis 3, 4
For NAFLD/MASLD: The threshold remains <1.3 for those under 65, with reassessment every 1-3 years recommended 1
For Hepatitis B: A score <1.0 is optimal for excluding advanced fibrosis 5
Important Caveats
While your low FIB-4 score is reassuring, recognize these limitations:
- FIB-4 will miss approximately 10% of individuals with advanced fibrosis even at low scores 1
- The score performs less optimally in patients with type 2 diabetes, where false positives are more common in the intermediate range 1
- FIB-4 accuracy is reduced in younger patients (under 35) and elderly patients (over 65) 1
- The score may not detect moderate fibrosis (F2) at initial assessment, though these patients should be identified during future assessments as disease progresses 2
Recommended Follow-Up
Repeat FIB-4 testing in 2-3 years if you have any of the following risk factors 1, 2:
- Type 2 diabetes mellitus
- Abdominal obesity plus ≥1 additional metabolic risk factor
- Persistently elevated liver enzymes
- Known chronic liver disease
This interval is supported by prospective data showing only 12% of patients with type 2 diabetes had significant increases in liver stiffness after 3 years 2.
When to Seek Earlier Reassessment
Consider earlier re-evaluation if you develop:
- New elevation in liver enzymes (AST/ALT)
- Clinical signs of liver disease progression
- New metabolic risk factors
- Symptoms suggesting liver dysfunction
No liver biopsy, elastography, or hepatology referral is indicated at this time given your low-risk score 1, 2.